Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557737 | 0.97 | HPGD (0.58) | HPGDALDH1A1POLBADORA2AAKT1 | |
| SCHEMBL557606 | 0.84 | HPGD (0.42) | HPGDHSD17B10 | |
| SCHEMBL557499 | 0.82 | VNN1 (0.45) | HPGD | |
| SCHEMBL10174957 | 0.76 | PLAU (0.37) | HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL17350917 | 0.74 | CSF1R (0.41) | HPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL17350560 | 0.74 | RIPK2 (0.44) | ALDH1A1AKT1AKT2 | |
| SCHEMBL557497 | 0.74 | JMJD6 (0.42) | HPGDSMN1; SMN2ALDH1A1HSD17B10AKT1 | |
| SCHEMBL17350547 | 0.72 | HSD11B1 (0.51) | HPGDSMN1; SMN2ALDH1A1HSD17B10GRIA3 | |
| SCHEMBL23675137 | 0.71 | HPGD (0.64) | HPGDSMN1; SMN2ALDH1A1POLBHSD17B10 | |
| SCHEMBL31525 | 0.71 | HPGD (0.77) | HPGDSMN1; SMN2ALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203449-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| EP-2197880-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8859582-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859583-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035152-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8076354-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-13 | — | — | US | disclosed |
| US-8071614-B2 | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035153-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HPGD 1667/4885SMN1; SMN2 4122/4885ALDH1A1 3442/4885 |
| US-20100331296-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, CDK1 | HPGD 1667/4885SMN1; SMN2 4122/4885ALDH1A1 3442/4885 |
| US-20100286113-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, BTK | HPGD 2230/4885SMN1; SMN2 4475/4885ALDH1A1 3554/4885 |
| US-20120035152-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BMX, BTK | HPGD 2230/4885SMN1; SMN2 4475/4885ALDH1A1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.